Why was zelnorm pulled

The FDA said one of the 13 affected patients in the Zelnorm group had died. Of those taking placebo, only one had symptoms suggesting the beginning of a stroke, which went away without complication. But he said the difference between the groups was "very concerning" and enough to warrant the drug's recall. Novartis told the FDA on February 22 about preliminary findings of cardiovascular problems, Jenkins said.

After requesting more data and doing its own review, the FDA asked Novartis to withdraw the drug on March Zelnorm is the second drug in two days to come off the U. On Thursday, the FDA said makers of Parkinson's drug pergolide were pulling it because of a risk of heart-valve damage.

Novartis lowered its financial targets and said it would make provisions for costs related to the suspension in the first quarter of Although its use is limited to women aged under 65 years without any previous ischemic cardiac disease, what is even more limited is our access to promotility drugs that can help with constipation.

Promotility drugs such as tegaserod or prucalopride are great additions to our current medications because they work by using a different mechanism. The more different mechanisms of actions we have available to us, the better chances we have to be able to manage constipation.

While there is some theoretical risk for cardiac complications, the FDA reviewed the literature and concluded there is no increased risk associated with the use of tegaserod. Another nice feature associated with tegaserod is that it has promotility effects on the entire GI tract, so it may have additional benefit in patients who have gastroparesis as well as constipation.

Healio News Gastroenterology Motility. Perspective from William D. Perspective from Zubair Malik, MD. Read next. April 03, Receive an email when new articles are posted on.

Please provide your email address to receive an email when new articles are posted on. You've successfully added to your alerts. You will receive an email when new content is published.

The product could have stayed on the market with a label change, he said. The patients taking sugar pills in the tests had an unexpectedly low rate of heart attacks, Vasella said.

Sales were also halted in Canada, and Novartis is talking to health agencies in other countries. The drug will stay on the market in Switzerland.

Cathy Williams, who lives in Bentleyville, Pennsylvania, said she plans to contact her doctor to evaluate her options. GlaxoSmithKline Plc withdrew Lotronex in after the drug was linked to abdominal bleeding and deaths. Never miss a story!